Evommune stock price surged after positive results from the Phase 2a trial of eczema medication

Investing.com – Evommune Inc. (NYSE:EVMN) stock rose 64% after the clinical-stage biotechnology company announced positive preliminary results from its Phase 2a trial of EVO301 in patients with moderate to severe atopic dermatitis.

The trial met its primary efficacy endpoint, showing a 33% improvement in the Eczema Area and Severity Index (EASI) compared to placebo at week 12. EVO301 is a long-acting fusion protein targeting the interleukin-18 pathway, with significant reductions in EASI scores at weeks 4, 8, and 12 compared to placebo.

This randomized, double-blind, placebo-controlled study enrolled 70 patients who received intravenous injections of 5 mg/kg on days 1 and 28 over a 12-week period. Results showed that 23% of patients treated with EVO301 achieved a validated investigator global assessment (vIGA-AD) score of 0 or 1, compared to 0% in the placebo group.

“These data highlight that pathways beyond Th2 biology can significantly improve disease activity in atopic dermatitis. EVO301’s ability to target a novel IL-18 mechanism and demonstrate clinically relevant therapeutic activity without side effects could provide real benefits for patients with such a heterogeneous disease,” said Dr. Mark G. Lebwohl, Chair of the Department of Dermatology and Honorary Chair of Clinical Therapeutics at Icahn School of Medicine at Mount Sinai.

The drug demonstrated a favorable safety profile, with no reports of related serious or severe adverse events, and no treatment-related discontinuations. Pharmacokinetic data support a once-every-four-weeks dosing schedule.

Evommune plans to advance EVO301 into a Phase 2b dose-ranging trial using a subcutaneous formulation and is exploring other indications, including ulcerative colitis.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.